The chief medical officer and chief development officer at BlueRock Therapeutics discussed the promise behind bemdaneprocel and its unique mechanism of action relative to other Parkinson disease treatments. [WATCH TIME: 3 minutes]
Amit Rakhit, MD
Advertisement
Articles by Amit Rakhit, MD
The chief medical officer and chief development officer at BlueRock Therapeutics provided perspective on newly presented data investigating a cell therapy for patients with Parkinson disease. [WATCH TIME: 4 minutes]
Advertisement
Latest Updated Articles
Positive 24-Month Data of Cell Therapy Bemdaneprocel in Parkinson Disease: Amit Rakhit, MDPublished: October 1st 2024 | Updated:
- Mechanism of Stem Cell Therapy Bemdaneprocel for Parkinson Disease: Amit Rakhit, MD
Published: October 9th 2024 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Paraneoplastic Neurologic Syndromes Present Before Testicular Germ Cell Tumor Diagnosis, Study Shows
2
This Week on NeurologyLive® — October 27, 2025
3
Enhancing Stroke Systems of Care
4
Benzodiazepines and Antipsychotics Tied to Higher Mortality in Hospice Patients With Dementia
5
